GYRE
Income statement / Annual
Last year (2023), Gyre Therapeutics, Inc.'s total revenue was $113.45 M,
an increase of 14,188.41% from the previous year.
In 2023, Gyre Therapeutics, Inc.'s net income was -$92.93 M.
See Gyre Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$113.45 M |
$794,000.00 |
$7.34 M |
$20.95 M |
$0.00 |
$6,000.00 |
$1.02 M |
$399,000.00 |
$1.75 M |
$275,000.00 |
| Cost of Revenue |
$4.64 M
|
$798,000.00
|
$7.38 M
|
$9.16 M
|
$43.86 M
|
$21.47 M
|
$12.85 M
|
$10.56 M
|
$5.96 M
|
$5.27 M
|
| Gross Profit |
$108.81 M
|
-$4,000.00
|
-$42,000.00
|
$11.79 M
|
-$43.86 M
|
-$21.47 M
|
-$11.83 M
|
-$10.16 M
|
-$4.21 M
|
-$4.99 M
|
| Gross Profit Ratio |
0.96
|
-0.01
|
-0.01
|
0.56
|
0
|
-3578
|
-11.62
|
-25.45
|
-2.4
|
-18.15
|
| Research and Development Expenses |
$13.78 M
|
$13.04 M
|
$68.89 M
|
$52.98 M
|
$43.86 M
|
$21.47 M
|
$12.85 M
|
$11.56 M
|
$5.96 M
|
$19.50 M
|
| General & Administrative Expenses |
$14.66 M
|
$17.37 M
|
$18.96 M
|
$16.18 M
|
$13.42 M
|
$12.35 M
|
$9.99 M
|
$9.26 M
|
$9.59 M
|
$10.17 M
|
| Selling & Marketing Expenses |
$61.16 M
|
$54.24 M
|
$44.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$75.82 M
|
$17.37 M
|
$18.96 M
|
$16.18 M
|
$13.42 M
|
$12.35 M
|
$9.99 M
|
$9.26 M
|
$9.59 M
|
$10.17 M
|
| Other Expenses |
$86.44 M
|
-$517,000.00
|
-$78,000.00
|
$568,000.00
|
-$46,000.00
|
$1.65 M
|
$261,000.00
|
$86,000.00
|
$0.00
|
$318,000.00
|
| Operating Expenses |
$176.04 M
|
$30.40 M
|
$87.85 M
|
$69.16 M
|
$57.28 M
|
$33.83 M
|
$22.84 M
|
$20.82 M
|
$15.55 M
|
$29.67 M
|
| Cost And Expenses |
$180.68 M
|
$31.20 M
|
$95.23 M
|
$78.32 M
|
$57.28 M
|
$33.83 M
|
$22.84 M
|
$20.82 M
|
$15.55 M
|
$29.67 M
|
| Interest Income |
$0.00
|
$537,000.00
|
$39,000.00
|
$1.13 M
|
$2.10 M
|
$3.77 M
|
$261,000.00
|
$3.47 M
|
$518,000.00
|
$585,000.00
|
| Interest Expense |
$0.00
|
$717,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.48 M
|
$23,000.00
|
| Depreciation & Amortization |
$1.11 M
|
$1.13 M
|
$290,000.00
|
$138,000.00
|
$146,000.00
|
$149,000.00
|
$173,000.00
|
$389,000.00
|
$470,000.00
|
$351,000.00
|
| EBITDA |
$20.33 M |
$10.33 M |
-$87.60 M |
-$57.37 M |
-$57.28 M |
-$33.82 M |
-$21.82 M |
-$16.95 M |
-$12.81 M |
-$29.71 M |
| EBITDA Ratio |
0.18
|
-65.68
|
-11.94
|
-2.74
|
0
|
-5637
|
-21.44
|
-42.47
|
-7.32
|
-103.49
|
| Operating Income Ratio |
-0.59
|
-10.85
|
-11.98
|
-2.74
|
0
|
-5637
|
-21.44
|
-51.17
|
-7.89
|
-108.05
|
| Total Other Income/Expenses Net |
-$9.74 M
|
$209,000.00
|
-$39,000.00
|
$1.13 M
|
$2.10 M
|
$3.77 M
|
$261,000.00
|
$3.47 M
|
-$960,000.00
|
$575,000.00
|
| Income Before Tax |
-$76.97 M
|
-$7.89 M
|
-$87.93 M
|
-$56.24 M
|
-$55.18 M
|
-$30.06 M
|
-$21.56 M
|
-$16.95 M
|
-$14.76 M
|
-$29.14 M
|
| Income Before Tax Ratio |
-0.68
|
-9.94
|
-11.98
|
-2.68
|
0
|
-5009.17
|
-21.18
|
-42.47
|
-8.44
|
-105.96
|
| Income Tax Expense |
$8.52 M
|
$348,000.00
|
-$39,000.00
|
-$699,000.00
|
-$2.29 M
|
$3.77 M
|
-$173,000.00
|
$3.08 M
|
$518,000.00
|
$3.48 M
|
| Net Income |
-$92.93 M
|
$2.30 M
|
-$87.93 M
|
-$55.54 M
|
-$52.89 M
|
-$30.06 M
|
-$21.56 M
|
-$16.95 M
|
-$14.76 M
|
-$32.62 M
|
| Net Income Ratio |
-0.82
|
2.9
|
-11.98
|
-2.65
|
0
|
-5009.17
|
-21.18
|
-42.47
|
-8.44
|
-118.63
|
| EPS |
-1.41 |
0.0362 |
-2.87 |
-2.9 |
-4.41 |
-2.68 |
-6.3 |
-21.76 |
-49.99 |
-101.4 |
| EPS Diluted |
-1.41 |
0.03 |
-2.87 |
-2.9 |
-4.41 |
-2.68 |
-6.3 |
-21.76 |
-49.99 |
-101.4 |
| Weighted Average Shares Out |
$65.83 M
|
$76.74 M
|
$30.64 M
|
$19.18 M
|
$12.00 M
|
$11.21 M
|
$3.42 M
|
$778,780.00
|
$295,272.00
|
$321,719.00
|
| Weighted Average Shares Out Diluted |
$65.83 M
|
$75.69 M
|
$30.64 M
|
$19.18 M
|
$12.00 M
|
$11.21 M
|
$3.42 M
|
$778,780.00
|
$295,272.00
|
$321,719.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
